177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, Shrawan Kumar Singh
Topics & Concepts
DocetaxelMedicineProstate cancerChemotherapyUrologyClinical endpointOncologyRandomizationInternal medicineProstate-specific antigenRandomized controlled trialConfidence intervalProstateCancerProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment